Resverlogix Corp. (TSE:RVX) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Resverlogix Corp. has announced a strategic financial maneuver by extending their US$6.0 million debenture with Hepalink for an additional two years, now maturing on May 13, 2026, while also removing Hepalink’s conversion rights and increasing the interest rate from 12% to 18%. The company, a leader in epigenetic therapies, is working towards advancing treatments for cardiovascular disease and other chronic conditions. The amendment awaits formal documentation and approvals, including the nod from the Toronto Stock Exchange.
For further insights into TSE:RVX stock, check out TipRanks’ Stock Analysis page.